Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Fluticasone/Salmeterol Respirent vs Advair Diskus in Healthy Volunteers
NCT03820180Phase 1Completed
- Sponsor
- Respirent Pharmaceuticals Co. Ltd.
- Start
- Jan 2019
- Primary completion
- Feb 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fluticasone propionate and salmeterol in asthma and chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Respirent Pharmaceuticals Co. Ltd. Primary endpoints: Area Under the Curve from time 0 to last measurable concentration and Maximum Plasma Concentration. Started Jan 2019; status: completed.
02
Drugs
fluticasone propionatesalmeterol
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03820180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03820180.